Redox-responsive degradable prodrug nanogels for intracellular drug delivery by crosslinking of amine-functionalized poly(N-vinylpyrrolidone) copolymers.
Amination
Antibiotics, Antineoplastic
/ administration & dosage
Cell Survival
/ drug effects
Cross-Linking Reagents
/ chemistry
Delayed-Action Preparations
/ chemistry
Doxorubicin
/ administration & dosage
Drug Delivery Systems
Drug Liberation
Gels
/ chemistry
HeLa Cells
Humans
Neoplasms
/ drug therapy
Oxidation-Reduction
Degradable
Drug delivery
Nanogel
Prodrug
Redox-responsive
Tunable crosslinking density
Journal
Journal of colloid and interface science
ISSN: 1095-7103
Titre abrégé: J Colloid Interface Sci
Pays: United States
ID NLM: 0043125
Informations de publication
Date de publication:
22 Mar 2019
22 Mar 2019
Historique:
received:
21
11
2018
revised:
09
01
2019
accepted:
11
01
2019
pubmed:
29
1
2019
medline:
23
7
2019
entrez:
29
1
2019
Statut:
ppublish
Résumé
Facile approaches for the development of new tailored drug carriers are of high importance for the controlled administration of drugs. Herein we report a method for the synthesis of water-soluble reactive copolymers with well-defined architectures for fabrication of redox-sensitive degradable prodrug nanogels for intracellular drug release. Primary amine-functionalized statistical copolymers were obtained by hydrolysis of poly(N-vinylpyrrolidone-co-N-vinylformamide) copolymers which were synthesized via Reversible Addition-Fragmentation chain-Transfer (RAFT) polymerization. Redox-sensitive degradable nanogels with varying crosslinking densities were synthesized with a redox-sensitive cross-linker. Doxorubicin (DOX) was loaded to form prodrug nanogels (DNG) with hydrodynamic radius from 142 nm to 240 nm. The nanogels demonstrated slower degradation and retarded drug release rate with increased crosslinking density in the presence of 10 mM reduced glutathione (GSH) at 37 °C. The in vitro release studies revealed that maximum 85% DOX was released in 24 h under a reductive environment. Intracellular drug release profiles in HeLa cells indicated that the DOX delivery rate was tunable via varying crosslinking density of the nanogels. Cell viability assay demonstrated that the blank nanogels were biocompatible in wide concentrations up to 0.5 mg/mL while the DOX-loaded nanogels displayed medium antitumor activity with IC50 (half-maximal inhibitory concentration) of 1.80 μg/mL, 2.57 μg/mL, 3.01 μg/mL for DNG5, DNG10 and DNG15 respectively.
Identifiants
pubmed: 30690386
pii: S0021-9797(19)30061-X
doi: 10.1016/j.jcis.2019.01.049
pii:
doi:
Substances chimiques
Antibiotics, Antineoplastic
0
Cross-Linking Reagents
0
Delayed-Action Preparations
0
Gels
0
Doxorubicin
80168379AG
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
612-622Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.